Literature DB >> 11517152

The effect of GHRH on somatotrope hyperplasia and tumor formation in the presence and absence of GH signaling.

R D Kineman1, L T Teixeira, G V Amargo, K T Coschigano, J J Kopchick, L A Frohman.   

Abstract

Excessive GHRH stimulation leads to somatotrope hyperplasia and, ultimately, pituitary adenoma formation in the metallothionein promoter-driven human GHRH (hGHRH) transgenic mouse. This pituitary phenotype is similar to that observed in humans with ectopic production of GHRH. In both mice and man, GHRH hyperstimulation also results in dramatic increases in circulating GH and IGF-I. To determine whether GH/IGF-I modulates the development and growth rate of GHRH-induced pituitary tumors, pituitary growth and histology were evaluated in mice generated from cross-breeding metallothionein promoter-driven hGHRH transgenic mice with GH receptor binding protein (GHR) gene disrupted mice (GHR(-/-)). Expression of the hGHRH transgene in 2-month-old GHR intact (GHR(+)) mice resulted in the doubling of pituitary weight that was largely attributed to an increase in the number of GH-immunopositive cells. Pituitary weight of GHR(+) hGHRH mice did not significantly change between 2 and 6 months of age, whereas at 12 months, weights increased up to 100-fold those of GHR(+) pituitaries, and 70% of the glands contained grossly visible adenomas. All adenomas stained positively for GH, whereas some showed scattered PRL staining. Pituitaries of GHR(-/-) mice were half the size of those of GHR(+) mice. Although reduced in size, the histological features of GHR(-/-) mouse pituitaries were suggestive of somatotrope hyperplasia. Despite evidence of somatotrope hyperplasia, pituitaries from GHR(-/-) mice as old as 28 months of age were similar in size to those of 2-month-old mice and did not show signs of adenoma formation. Expression of the hGHRH transgene in GHR(-/-) mice did not significantly increase pituitary size between 2 and 6 months of age. However, at 12 months the majority of GHR(-/-), hGHRH pituitaries developed adenomas with mean pituitary weight and histological features similar to those of GHR(+), hGHRH mice. These observations demonstrate that intact GH signaling is not required for GHRH tumor formation. Although the majority of GHR(+), hGHRH and GHR(-/-), hGHRH pituitaries developed tumors by 12 months of age, a small subset remained morphologically indistinct from those at 2 months of age. These observations taken together with the fact that overt tumor formation is preceded by a static pituitary growth phase between 2 and 6 months, indicates that protective mechanisms are in place to maintain pituitary mass despite hGHRH hyperstimulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517152     DOI: 10.1210/endo.142.9.8382

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

Review 2.  Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse.

Authors:  Edward O List; Lucila Sackmann-Sala; Darlene E Berryman; Kevin Funk; Bruce Kelder; Elahu S Gosney; Shigeru Okada; Juan Ding; Diana Cruz-Topete; John J Kopchick
Journal:  Endocr Rev       Date:  2010-12-01       Impact factor: 19.871

3.  Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: clinical experience following tumor resection and long-acting octreotide therapy.

Authors:  Peter W Butler; Craig S Cochran; Maria J Merino; Dao M Nguyen; David S Schrump; Phillip Gorden
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

4.  DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Nan Deng; Evelyn Ding; Masaaki Yamamoto; Adam Mamelak; Vera Chesnokova; Artak Labadzhyan; Shlomo Melmed
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

5.  Use of the metallothionein promoter-human growth hormone-releasing hormone (GHRH) mouse to identify regulatory pathways that suppress pituitary somatotrope hyperplasia and adenoma formation due to GHRH-receptor hyperactivation.

Authors:  Raul M Luque; Beatriz S Soares; Xiao-ding Peng; Sonia Krishnan; Jose Cordoba-Chacon; Lawrence A Frohman; Rhonda D Kineman
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

6.  A New Perspective on Regulation of Pituitary Plasticity: The Network of SOX2-Positive Cells May Coordinate Responses to Challenge.

Authors:  Paul R Le Tissier; Joanne F Murray; Patrice Mollard
Journal:  Endocrinology       Date:  2022-08-01       Impact factor: 5.051

7.  Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients.

Authors:  Nienke R Biermasz; Jan W A Smit; Alberto M Pereira; Marijke Frölich; Johannes A Romijn; Ferdinand Roelfsema
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.